WallStreetZenWallStreetZen

NASDAQ: CYCN
Cyclerion Therapeutics Inc Stock Ownership - Who owns Cyclerion Therapeutics?

Insider buying vs selling

Have Cyclerion Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Terrance McGuireDirector2023-08-098$3.40
$27.16Sell

1 of 1

CYCN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CYCN insiders and whales buy or sell their stock.

CYCN Shareholders

What type of owners hold Cyclerion Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Slate Path Capital LP264.11%7,157,601$20.40MInsider
Terrance McGuire28.46%771,191$2.20MInsider
Amy W. Schulman23.38%633,625$1.81MInsider
Peter M. Hecht13.95%377,942$1.08MInsider
Slate Path Capital LP13.21%357,880$1.02MInstitution
Andreas Busch9.40%254,704$725.91kInsider
Mark G. Currie9.29%251,648$717.20kInsider
Mfn Partners Management LP6.25%169,460$482.96kInstitution
Tyndall Capital Partners L P6.08%164,777$469.61kInstitution
Fmr LLC5.99%162,327$462.63kInstitution

1 of 3

CYCN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CYCN9.83%90.17%Net Selling
TRVN11.24%88.76%Net Buying
TENX0.04%99.96%
PYPD66.54%0.00%
LGVN0.33%99.67%Net BuyingNet Buying

Cyclerion Therapeutics Stock Ownership FAQ

Who owns Cyclerion Therapeutics?

Cyclerion Therapeutics (NASDAQ: CYCN) is owned by 39.49% institutional shareholders, 362.07% Cyclerion Therapeutics insiders, and 0.00% retail investors. Slate Path Capital LP is the largest individual Cyclerion Therapeutics shareholder, owning 7.16M shares representing 264.11% of the company. Slate Path Capital LP's Cyclerion Therapeutics shares are currently valued at $20.03M.

If you're new to stock investing, here's how to buy Cyclerion Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.